Amphastar Pharmaceuticals (AMPH) Non-Current Deferred Tax Liability (2016 - 2023)

Amphastar Pharmaceuticals has reported Non-Current Deferred Tax Liability over the past 11 years, most recently at $201000.0 for Q3 2023.

  • For Q3 2023, Non-Current Deferred Tax Liability fell 16.94% year-over-year to $201000.0; the TTM value through Sep 2023 reached $201000.0, down 16.94%, while the annual FY2022 figure was $144000.0, 73.03% down from the prior year.
  • Non-Current Deferred Tax Liability for Q3 2023 was $201000.0 at Amphastar Pharmaceuticals, roughly flat from $201000.0 in the prior quarter.
  • Over five years, Non-Current Deferred Tax Liability peaked at $2.9 million in Q3 2021 and troughed at $144000.0 in Q4 2022.
  • A 5-year average of $724222.2 and a median of $748000.0 in 2020 define the central range for Non-Current Deferred Tax Liability.
  • Biggest five-year swings in Non-Current Deferred Tax Liability: surged 252.49% in 2021 and later plummeted 91.66% in 2022.
  • Year by year, Non-Current Deferred Tax Liability stood at $867000.0 in 2019, then dropped by 14.53% to $741000.0 in 2020, then decreased by 27.94% to $534000.0 in 2021, then tumbled by 73.03% to $144000.0 in 2022, then soared by 39.58% to $201000.0 in 2023.
  • Business Quant data shows Non-Current Deferred Tax Liability for AMPH at $201000.0 in Q3 2023, $201000.0 in Q2 2023, and $178000.0 in Q1 2023.